INTRODUCTION
As has been said often and will be pointed out on many future occasions, the sub~division of pharmaceutical agents into symptomatic and chemotherapeutic ones goes back to Paul Ehrlich and his time ( those days, with the :first serious attempts at drug~design (how has this optimism changed to a more sober, I did not say, sombre mood) this sharp subdivision has been somewhat blurred by the fact that a third group of compounds has joined the other two, comprising those of a prosthetic or restitutional nature. Among the latter we find some compounds which though not usually classed as chemotherapeutic agents, might also be applied in chemotherapy proper, that is the removal, or at least temporary control, of the cause of a number of diseases by drugs.
BIOLOGICAL BASIS This cause could be an invader as crude as a helminth or as subtle as a virus or it could be a changed host cell behaving as egocentrically as any foreign intruders, whether they may be bacterial, spirochaetal, protozoal or filtrable particles. Other meetings, and on this occasion other speakers, have discussed and will discuss the successful developments and the many victories of anti~microbial, anti-protozoal, and other anti-infectious drugs. Why is it then with all this experience behind them, that the scientists engaged in cancer research ( and, one may add, in virology), have so much less pronounced practical successes to their credit and that their progress is relatively so slow? It is obvious that the main reason for this isthat neoplastic and most virus diseases are bound up with internal events of cells and that the main problems ( Table 2 ) facing the combined front of chemists-biologists are the questions of transport to and into cell structures ( closely connected with vascularization ofthe tissues and the permeability of cells tobe attacked), and if killing-action or stasis is contemplated and hoped for, the question of selective concentration and toxicity. To these problems one has to add those of anti-growth or anti-mitotic effects on the so-called primary tumours and the most desirable, but as yet not realized, anti-invasion effects on the spread of malignant cells. If, on the other hand, it is possible in the future to find a therapy which might restitute missing essential cell constituents or which might help the cell to resist wrong biosynthetic stimulation exerted, e.g. by viruses or virus-like particles, then the discovery, availability and transport of such remedies (natural or imitatory in function) to and into the cells or nuclei may represent the main problems. Y ou see, in the case of cancers the tissues and cells to be treated may not be wholly accessible to drugs or restitutional agents. This could be due to an increasing lack ofvascularization of the internal parts of neoplasms, as demonstrated by Goldacre and Sylvenl, with the help of an easily penetrating dyestuff, lissamine green ( Figure 1 ). The questions arise whether it is sufficient to rely on the attack of the drug solely on the outside of a tissue region or whether it is necessary, as 30 20 Hamster kidney tumour cells 10 recommended by a number of workers, to combine chemotherapy with surgery, i.e. removal of the main tumour followed by post-operative drug treatment; or whether intra-arterial infusions or regional perfusions would be procedures of choice. One could discuss for hours the problern of permeability of cells themselves, that is the passage of drugs across the cellular membranes of whole cells, of their nuclei (and sometimes mitochondria) by passive, facilitated or active transport, phagocytosis, as discussed recently by Quastel et al. 2 , and pinocytosis; the latter, according to Holter 3 , more often occurring with tumour cells than with normal ones. We could talk about events concerning the cell surface and its different charge densities (Figure 2 ) which according to Ambrose et al. 4 may have some bearing on spreading and metastasizing tendencies, but all this would take me away from the principal line of this paper.
BORDERLINE THERAPIES
However, before dealing with a few aspects of a quasi-rational approach to the preparation of cheniicals, and of their properties and application to tumour-bearing animals and cancer patients, I must deal very briefly with matters which go, as some of you may think, beyond the confines of chemotherapy proper: they refer to (a) preventive medicine, (b) immunology, (c) virology and (d) endocrinology.
(a) It is not often remernbered that those ofus in cancer research who test organic and inorganic chemieals for their carcinogenic effects and try to relate chemical structure and physical properties of a series of compounds to their cancer-producing activity, study not only the possible origin of cancer and its development, but are concerned also with recommendations for removal of certain chemieals from manufacturing processes or from daily use either in foodstuffs, cosmetics or indirectly even in cigarettes or in the atmosphere (Table 3 ). In promulgating abstinence from or removal of 6 • It is the latter group which could represent a promise for a future immunochemical approach to cancer treatment. However, the antigenic potency of most of these tumour-specific constituents is low and their purification beset with great difficulties. However, this whole field on the fringe of cancer chemotherapy is on the move but there is no certainty as to its direction, and rapid and successful arrival. This wasborneout by a recent discussion at Helsinki, under the auspices of the In~ernational Union against Cancer 7 • (c) Closely connected with all this are the activities of the virologists in cancer, with Stanley 8 and Gross 9 leading and with more and more workers prohing into this fascinating problem. From the beginning it should be said that up to now there is no clear-cut evidence in favour ofviruses being the causative agent ofhuman neoplasms, except perhaps, and this is being investigated just now, in the case of malignant Iymphomas prevalent among children in some regions of Africa 10 • (This should not throw any doubt on the virus aetiology of murine leukaemias, polyomas, rabbit papilloma, and fowl sarcomas). One has also to distinguish between viruses or virus-like sub-cellular particles as inducing agents, to be fought perhaps with antiviral remedies, vaccines and anti-sera, and viruses as oncolytic agents. To touch on the latter first, Dr Alice Moore 11 , among others, is studying this approach which she has reviewed from time to time. For the worker in chemotherapeutics it would be most important to learn something about that part of the anti-tumour virus which is "oncolytic". We may one day see the preparation or synthesis of polynucleotides, either of DNA, RNA or messenger RNA-character which could act like an oncolytic virus solely on tumour cells. On the other hand, if the development of a neoplastic state is directly or indirectly due to a virus, it might be possible to find, according to Harris, interferon-like materials 12 which could, at some future date, assist cancer chemotherapy. But at the present time this is more like a pipe dream after laboratory hours. In any case, virus-produced tumours, if ever discovered in man, ought to require, in most cases, preventive treatment, because after the full establishment of the tumour and achievement of independence from causative agents anti-viral treatment would have little chance of success except in recurrent infections.
(d) The mechanistic role of hormones either in carcinogenesis or carcinotherapy is far from clear. Whether they influence enzyme action, protein synthesis or cell permeabilities, their application in the chemotherapy-of leukaemias ( cortisone, ACTH in acute forms), of breast and prostate cancer originated more in an empirical than in a rational manner. While in carcinoma of the prostate stilboestrol or stilboestrol diphosphate ( Table 4) is still the drug of choice, breast tumours in women · respond sometimes to oestrogens, sometimes to androgens and sometimes to adrenalectomy, hypophysectomy or pituitary-destroying procedures, all treatments called by Boyland 5 , as mentioned before, "negative chemotherapy". The modern trend of steroid research aims at the preparation of steroid derivatives which 
CARCINO-CHEMOTHERAPEUTIC AGENTS
This brings us to more recent developments of anti-tumour and antileukaemic drugs proper to be found under these headings ( group of potential remedies, in the true sense of the word, which in form of purified cellular constituents and enzyme models or enzymomimetics may help to change the aberrant cell into one which could be less dangeraus in its behaviour to the organism as a whole. Another group, (4), which I cannot discuss here, are natural products from micro-organisms or higher plants (including antibiotics, colchicine, and vinblastine).
(1) There is no necessity to bore you with the well-known history and details of the main types of biological alkylating agents ( Table 6) , the nitrogen mustards, metharre sulphonates, ethyleneimines and epoxides. What I wish to present to you today will touch on two principal directions in the sturlies of this group which in its clinical application is, so one has to confess, of use but a limited one; these agents act by destroying growing cells without possessing true selective toxicity nor a pronounced effect on the spread of cancer by invasion and metastases. One of these studies ain1s at better knowledge of the mechanism of action of these drugs, the other at improvement inside the Iimits set by their over-all·properties. Arising from researches carried out by two of my colleagues, Brookes and Lawley 13 , it is probable that the mutation-, anti-tumour and carcinogenic effects of these moieties of different strands (Figure 4) . The other advance refers to the work of two other colleagues, Roberts and Warwiek with "Myleran", a dimethanesulphonate, which in the rat seems to interact with thiol groups of 13, 1960) causally connected with the biological effects of these agellts but they ought to help in our understallding of some of the mechanistic details of action and in the Colltillued search for improved drugs.
(2) Such search is vital if one wishes to keep pace with the increasing demalld by the cliniciall for carcino-therapeutic agents which he is desirous of applying either Oll their own, or in combination with surgical or radiotherapeutic procedures. Work durillg the last few years has moved towards (Table 7) : (i) applicatioll ofthe carrier prillciple and (ii) of"latent" activity, (iii) towards utilizatioll of metabolic effects including that of pH gradients and (iv) selective protection of normal and selective sellsitization of llCOplastic tissues vis~a-vis drug effects. I call give you only a few illustratiolls in form of compoullds which belong to Olle or the other group or to several of these groups at the same time.
I
( i) While some workers have utilized amino-acids or peptides as carriers of cytotoxic groups, others have studied sugar-like moieties, pyrimidines, steroids, anti-malarials, etc. My colleagues and I have spent a number of years Oll the study of amillo-acid derivatives, especially those based on the naturally occurring phellylalallille and some of its peptides (Figures 6 and 7) . This researchwas also taken up, I am glad to say, by Russiall scielltists ullder o-isamers (meraphan) 17 and a nurober of di-and palypeptides. So far melphalan and sarcalysin have faund clinical use, especially in the treatment of malignant melanama and multiple myeloma; from a fundamental paint af view it is not uninteresting that a pentapeptide (CB 3305) 18 with M = 770, has accarding ta Shankman 19 , weight far weight, a similar inhibitory effect on the grawth of P. cerevisiae (L. citrovorum) as the parent substance melphalan with M = 305 ( Table 8) . ( Table 9) . Again, stereospecificity is af importance here in that only (ii) Going over to "latency", this means compounds carrying deactivated cytotoxic groups which under biological conditions and on release from, or by alteration of, their carrier regain their full destructive effects. I t can be achieved among others by combining a N-mustard group in form of an amide with an acidsuch as carboxylic, carbamic or phosphoric acid. In this manner the alkylating power of dichloroethylamino, in difference to ethyleneimino groups are diminished and the derivatives possess a low chemical and biological activity ( Table 10 ). Simple aliphatic amides with a (ClCH 2 CH 2 ) 2 N group arenot very easily prepared because they rearrange with relatively great facility into esters of hydroxyethylchloroethylamine. (iii) Let me draw your attention briefly to the possibility of utilizing F. HERGEL metabolic effects to improve the action of anti-tumour drugs. The preferential concentration of an anti-tumour drug in the target area may not only be promoted or achieved by the right carrier moiety, by a differentialliberation of an active moiety of a "latent" compound as mentioned just now, but also by making use of certain metabolic differences between normal and abnormal tissues, however slight in comparison with the much larger ones between host and invading organisms. One of the claims which has been made again and again since Warburg's discovery of the preponderance of aerobic and anaerobic glycolysis in cancer cells was that protones accumulate either as lactic or pyruvic acid in neoplastic tissue ( Table 11 ), and that the acidity of such cells increases with a concurrent fall in pH. This has been 23 who found considerable changes in pH in tumours after injection of glucose, fructose and in some cases after galactose, very likely measuring these in the intercellular fluid with electrodes ( Figure 9 ). So far we could not obtain the same dramatic drop with our rat tumours but glucose and fructose injections appear to increase the anti-tumour effects of basic alkylating agents ( Table  12 ) and more so of mannitol Myleran; unfortunately, however, their general toxicity, and to a slightly lesser degree their haemotoxicity (hone marrow damage) go up. Whether these observations support the pHgradient hypothesis or whether the injected sugars increase the Ievels of intermediates of the glycolytic pathway making its enzymes, hexokinase, fructose-1 : 6-diphosphatase or phosphorylase more vulnerable, or whether penetration of the drugs into cells and nuclei are favourably influenced, as they may depend on active transport phenomena, we do not know yet. We feel that these observations are worth while pursuing. The selective protec~ tion of normal organs with thiol compounds such as cysteine, and the selective sensitization of neoplastic tissue with porphyrins as claimed by various workers:. 4 and studied by my colleagues has not yet reached the state where, at least in our opinion, we can claim clear cut advances. But our investigations are continued unceasingly to achieve lower toxicities and greater selectivity inside the given limitations. 25 in 1947 used a folic acid analogue for the first time. But time is too short to deal with them properly. I hope to have your consent to trea t briefty instead more speculative aspects and leave aside anti-amino acids, anti-vitarnins (anti-coenzymes), and pyrimidine, purine and folic acid analogues, recent sturlies of which have given an insight into their mechanism of action and of specific drug resistance. The speculative approach refers to two working hypotheses; their final usefulness can only be judged by their future practical successes. One is being developed by Baker et al. 26 in the U.S.A., the other by my colleagues and myselfin London. Baker, starting from _the assumption that irreversible inhibitors of essential enzymes may be more effective than reversible and competitive ones, is studying the combination of the classical structure of the Iatter type, which fits on to the catalytic site, with a group producing covalent bonds by endoor exo-alkylation or acylation. This work aiming at an extension of the antagonist idea by non-classical means may produce, later, interesting drugs. (Figure 1 0) . Our scheme is probably just as speculative and ambitious. It rests on three assumptions: one, is it possible to re-introduce into tumour cells certain functional constituents of which these tumours are deficient; two, is it useful to raise Ievels of enzymes which regulate the catabolism of intermediates on which the tumour cell depends more than the normal one; and three, could all this be achieved with enzyme models, or as I called them, "enzymomimetics", that is relatively simple compounds or compound combinations, capable of imitating under in vivo conditions the true biocatalysts. Some of you may remernher that a number ofworkers including ourselves have found effects of purified enzyme preparations, such as xanthine oxidase or ribonuclease, on the growth rate of a spontaneaus mammary tumour in the ä64 CHEMOTHERAPY OF NEOPLASTIC AND RELATED DISEASES mouse 27 • Other workers succeeded in diminishing ascites tumours with DNAase 28 and asparaginase; enzymes, such as Iipase, proteinases etc. have been tested from time to time, especially on tissue cultures. But with all thesenatural materials the problern remains whether these large molecules, often from a different species, ever penetrate the target cells sufficiently and without immunological reactions. This is why we started to look for enzyme models to replace the natural products. One of the examples I wish to give you isthat of a model for cysteindesulphydrase. It would take a whole lecture of its own to explain the why and wherefores 29 , but may it suffice to say that there is a possibility that human leukaemic cells are more avid for sulphur-containing amino-acids such as cystine and cysteine ( according to Weisberger 30 ) than normal leucocytes and that a combination ofpyridoxal phosphate and V0 2 + (pyrvanal) was found by my colleague Harrap 31 to act as a cysteine-destroying agent in vitro andin vivo (Figures 11  and 12 ). Under in vivo conditions this expressed itselfin an inhibition offowl tumours implanted in the chorioa:llantoic membrane of the chicken egg ( Table 13 ) and in a fall of the white blood cell count in, so far, a very few patients with acute leukaemia.
CHEMOTHERAPY OF NEOPLASTIC AND RELATED DISEASßS ~---------------~----------------~-----------------
What we need to establish now is ,th~ r"".,..,. .. -· •. -' of such patients when given vitamin B 6 -tablets and sodium vanadate solution to effectively transform B 6 into pyridoxal or pyridoxal phosphate so that the meta! ion and the pro-coenzyme could diminish the cysteine pool. Work in this direction is being carried on in our Institute. Such work in human pathological chemistry, and I mentioned before the desirability of assessing differences in biochemical functionalities between tumour and tumour, and tumour and normal tissue, is of vital importance. An enormaus nurober of investigations have been carried out over the last 30 years or so on animal material. But there is great necessity to concentrate the resources and researches in many places on human cancers and leukaemias and to find out, apart from quantitative differences in cellular constituents ( enzymes, nucleic acids, etc.) and in metabolic rates, much more about the behaviour of human tissues vis-a-vis drugs. This could be clone in a nurober of ways, and at this point I can give you only a few examples. Some tumour samples from biopsies and major operations can be transformed into primary tissue cultures (see Ambrose et al. 32 ) which then can be exposed to various concentrations of a number of anti-tumour agents ( Figure 13 ). The LD 50 of the latter can be established and their effectiveness Facing page 366 assessed. In the case of a human malignant melanoma there appeared to be a difference in cytotoxic activity between otherwise closely related alkylating agents (melphalan and chlorambucil and thioTEPA). Another approach consists in determining after Wolberg 33 , the uptake of tritium-labelled uridine into tumour cells before and after exposure to chemotherapeutic agents. The amount of radioactive material is then estimated with the help of autoradiography of the tissue sample and the darnage to the nucleic acid anabolizing systems assessed. Again, other techniques would deal with the rate of glycolysis and respiration prior and subsequent to the application of drugs. Only if all this and many more investigations are carried out and, if possible, brought to the stage of a semi-routine test, shall we understand why certain tumours in certain patients respond to chemotherapy and others do not, why after successful first courses the tumours become resistant and why some primary cancers spread while others are held in check. In addition, any attempt ofthe surgeons and radiotherapists to come to a collaborative arrangement with the chemotherapist should be strongly supported by the latter and any help required of him given generously. Then we might see more than a relatively small, relatively shortlived number of clinical successes, one ofwhich I want to show you as a last illustration (Figures 14( a) and ( b) ). Hereisapatient with malignant melanoma prior to and after regional perfusion with melphalan. Such is the situation that we are most encouraged for our further labours by successes of this nature.
